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respectively. MRI-images of tumor recurrences were fused with the original planning-CT, and patterns of failure were deﬁned
according to the location of recurrence respect the isodose lines (IDL). Central recurrences were deﬁned when the recurrence
was located within the 65Gy-IDL, local recurrence in the 55–60Gy-IDL, marginal recurrence in the 30–50Gy-IDL and distal failure
when the recurrence was located outside the 30Gy-IDL.
Results. From January 2007 to May 2012, 48 pats with a MFU of 39.12 months (9–73 months) were enrolled in the study. Twenty-
two pats (44.9%), 2-pats (4.1%), 0-pats (0%), 4-pats (8.2%) and 7-pats (14.3%) had central, local, marginal, central plus local and
distal recurrences, respectively. Local–central control was achieved in 19-pats (42%). Central recurrences were more frequently
observed in pats with unmethylated-MGMT (13/19 pats, 68%). Median OS and PFS were 21 months and 14 months, respectively.
Conclusions. In this series, the patterns of failure in GB were predominantly local–central (50%). Using 11C-MET-PET planning
images and highly conformal dose distribution, we have not observed an increase in marginal recurrences rates. Patients with
unmethylated-MGMT tumors have more local–central recurrences. Future studies with the inclusion of a greater number of pats
are warranted to conﬁrm these data.
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Purpose. To determine, at ﬁrst progression, if patients receiving anti-VEGF show different patterns of relapse compared with
patients treated with conventional concomitant RT/CT.
Methods. Patients fromour center included in a prospective trial designed for neoadjuvant treatment in only biopsied glioblastoma
patients are analyzed. All GD-enhanced T1 and FLAIR MRI sequences were reviewed and co-registered with treatment planning
done just before radiotherapy. Patterns of relapse after radiotherapy were deﬁned as follows: A. all relapses were within the
95% of isodose; B. all relapses were between 95% and 50% of isodose; C. all relapses were outside 50% of isodose. Two groups of
patients were included; those treated with temozolamide (TMZ) alone (TMZ group) before radiotherapy and those who received
neoadjuvant TMZ and Bevacizumab (BV) (TMZ+BV group).
Results. Nineteen patients are included at ﬁrst analysis. Thirteen had progressed after complete radiation (RDT) treatment and
were available for evaluation (4 in TMZ group and 9 in TMZ+BV group). Mean time to progression after RDT was 150 days in
TMZ-group and 151.8 days in TMZ+BV group. GD-enhanced T1 did not show differences in patterns of relapse between both
groups, being the pattern A the most common (100% in TZM group vs 88.8% in TMZ+BZM group). However, FLAIR sequence
showed more B and C patterns in both groups. A–C patterns were observed in 25%, 75% and 0% in TMZ group; and 33.3% for each
pattern in TMZ+BV group. Results showed a trend to detect more C patterns of relapse in patients who had received anti-VEGF
treatment.
Conclusions. These results show that FLAIR sequence is essential in deﬁning the patterns of relapse in patients treated with
neoadjuvant treatment. Sample will be updated at presentation. Deﬁning patterns of relapse with new drugs could be deﬁnitive
for radiotherapy volumes and doses.
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Introduction. Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy
and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment
of these patients. This review is an analysis of our patients with anaplastic oligodendroglioma and oligoastrocytoma.
Material and methods. We have reviewed the treatment results in 12 patients, ten with intracranial anaplastic oligodendroglioma
and two with anaplastic oligoastrocytoma, treated from 2007 through 2012 at the Hospital General de Ciudad Real. Ten patients
received adjuvant radiotherapy with median dose of 60Gy and concomitant Temozolamide and two treated with RTOG BR0103
scheme. The median age was 45 years old. Eleven patients had determined the co-delection 1p19q, 2 of them had a negative 1p,
one had negative 1p19q and the rest, had a co-deletion.
